| THE ROLE OF THE SOLUBLE SPECIFIC SUBSTANCE IN ORAL IMMUNIZATION AGAINST PNEUMOCOCCUS TYPE I. | |
| | |
| Jump to Full Text | |
MedLine Citation:
|
PMID: 19869967 Owner: NLM Status: PubMed-not-MEDLINE |
Abstract/OtherAbstract:
|
1. Feeding the purified soluble specific substance of Type I pneumococcus protects rats against an intraperitoneal injection of the virulent organism. 2. This increased resistance resembles that obtained when the intact (dead) or dissolved bacteria are fed, as follows: (a) one feeding is sufficient, (b) the interval between the feeding and the appearance of the immunity is the same, (c) the duration is approximately the same, (d) when the immunity is exhausted it can be renewed by a new feeding, (e) the immunizing action is type-specific. 3. The differences between the effects of feeding the purified specific substance and the intact or dissolved organism to rats, appear to be quantitative rather than qualitative, the proportion of animals protected and the height of the immunity being generally, though not always, less in the case of the former. 4. In contrast to the immunizing action which the soluble specific substance possesses when administered to rats, feeding it to mice failed to protect them. Neither were mice definitely immunized by parenteral administration. 5. A sodium glycocholate solution of Pneumococcus Type I lost part of its immunizing activity on standing for 1 year. 6. The failure to immunize mice and the loss of activity of the bile salt solution of pneumococcus, on standing, are discussed in terms of (a) the possible presence of a second cell constituent which is active by mouth, and (b) a possible intramolecular change in the type-specific polysaccharide associated with a loss of immunizing action while retaining the precipitin reaction. |
| | |
Authors:
|
V Ross |
Related Documents
:
|
20636237 - Effect of recombinant human keratinocyte growth factor (Δ23rhukgf, palifermin) o... 9389537 - Changes in 1,25-(oh)2d3 synthesis and its receptor expression in spleen cell subpopulat... 362217 - Migration inhibition factor study in histoplasma capsulatum. 100957 - Electron microscopy of cellular immunity reactions in b-cell deprived rabbits. thymus d... 21566897 - Aids from an oncological viewpoint - paradoxical immunodeficiency by helper t-cell prol... 16041517 - Gaseous nitrogen oxide repressed benzo[a]pyrene-induced human lung fibroblast cell apop... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Journal of experimental medicine Volume: 54 ISSN: 0022-1007 ISO Abbreviation: J. Exp. Med. Publication Date: 1931 Nov |
Date Detail:
|
Created Date: 2010-06-23 Completed Date: 2010-06-23 Revised Date: 2010-09-27 |
Medline Journal Info:
|
Nlm Unique ID: 2985109R Medline TA: J Exp Med Country: United States |
Other Details:
|
Languages: eng Pagination: 899-923 Citation Subset: - |
Affiliation:
|
Bureau of Laboratories, Department of Health of the City of New York, New York. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
| Full Text | |
|
Journal Information Journal ID (nlm-ta): J Exp Med ISSN: 0022-1007 ISSN: 1540-9538 Publisher: The Rockefeller University Press |
Article Information Download PDF  Copyright © Copyright, 1931, by The Rockefeller Institute for Medical Research New York Received Day: 28 Month: 7 Year: 1931 Print publication date: Day: 30 Month: 11 Year: 1931 Volume: 54 Issue: 6 First Page: 899 Last Page: 923 ID: 2180305 PubMed Id: 19869967 |
| THE RÔLE OF THE SOLUBLE SPECIFIC SUBSTANCE IN ORAL IMMUNIZATION AGAINST PNEUMOCOCCUS TYPE I | |
| Victor Ross | |
| From the Bureau of Laboratories, Department of Health of the City of New York, New York |
|
Article Categories:
|
|
Previous Document: ORAL IMMUNIZATION AGAINST PNEUMOCOCCUS TYPES II AND III AND THE NORMAL VARIATION IN RESISTANCE TO TH...
Next Document: THE ROLE OF THE SOLUBLE SPECIFIC SUBSTANCE IN ORAL IMMUNIZATION AGAINST PNEUMOCOCCUS TYPES II AND II...